We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA and EMA Launch Parallel Scientific Advice Pilot for Complex Generic Products
FDA and EMA Launch Parallel Scientific Advice Pilot for Complex Generic Products
The FDA and the European Medicines Agency (EMA) have launched a pilot program to provide parallel scientific advice to applicants seeking marketing authorization from the EMA for hybrid products and for those filing abbreviated new drug applications (ANDAs) with the FDA for complex generic drugs.
